Apeloa Pharmaceutical Co.,Ltd
000739
Rangering i aksjer
#4291
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Aksjekurs
$3.13
Markedsverdi
$3.62B
Endring (1 dag)
-1.42%
Endring (1 år)
46.59%
Land
CN
Handel Apeloa Pharmaceutical Co.,Ltd (000739)
Kategori
Healthcare
Antall utestående aksjer for Apeloa Pharmaceutical Co.,Ltd (000739)
Antall utestående aksjer per June 2026: 1.13B
Ifølge Apeloa Pharmaceutical Co.,Ltd sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 1.13B. Ved slutten av December 2024 hadde selskapet 1.16B utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Apeloa Pharmaceutical Co.,Ltd (000739) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 1.13B | -2.09% |
| 2025 | 1.15B | -0.45% |
| 2024 | 1.16B | -0.93% |
| 2023 | 1.17B | 0.00% |
| 2022 | 1.17B | -0.78% |
| 2021 | 1.18B | 0.00% |
| 2020 | 1.18B | 0.00% |
| 2019 | 1.18B | 0.00% |
| 2018 | 1.18B | 2.52% |
| 2017 | 1.15B | 0.58% |
| 2016 | 1.14B | -0.33% |
| 2015 | 1.15B | 6.80% |
| 2014 | 1.07B | 34.75% |
| 2013 | 796.95M | 63.70% |
| 2012 | 486.82M | -49.99% |
| 2011 | 973.47M | 41.65% |
| 2010 | 687.25M | 2.98% |
| 2009 | 667.33M | -0.02% |
| 2008 | 667.43M | 5.15% |
| 2007 | 634.73M | 11.69% |
| 2006 | 568.31M | -10.46% |
| 2005 | 634.73M | 0.00% |
| 2004 | 634.73M | 0.00% |
| 2003 | 634.73M | 0.00% |
| 2002 | 634.73M | 0.00% |
| 2001 | 634.73M | 0.00% |
| 2000 | 634.73M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 112.49% |
IN
|
